Libtayo® (cemiplimab) in combination with chemotherapy receives positive chmp opinion for the treatment of advanced pd-l1 positive non-small cell lung cancer (nsclc)

Recommendation based on a phase 3 trial demonstrating superior survival outcomes for libtayo plus chemotherapy compared to chemotherapy alone recommendation based on a phase 3 trial demonstrating superior survival outcomes for libtayo plus chemotherapy compared to chemotherapy alone
REGN Ratings Summary
REGN Quant Ranking